Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Ikhwan Rinaldi & Kevin Winston. (2023) Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review. Journal of Blood Medicine 14, pages 261-277.
Read now
Read now
Marwa S Hamza, Samia A Shouman, Raafat Abdelfattah, Heba S Moussa & Mervat M Omran. (2022) Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients. Drug Design, Development and Therapy 16, pages 1595-1604.
Read now
Read now
Deepthi Boddu, Priyakumari Thankamony, C.S. Guruprasad, Manjusha Nair, Binitha Rajeswari & Shwetha Seetharam. (2019) Effect of imatinib on growth in children with chronic myeloid leukemia. Pediatric Hematology and Oncology 36:4, pages 189-197.
Read now
Read now
Adnan Asif Parvez Ghias, Shahzeem Bhayani, David J. Gemmel & Sudershan K. Garg. (2018) Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity. Journal of Community Hospital Internal Medicine Perspectives 8:2, pages 87-91.
Read now
Read now
Sabina Novaković, Anamarija Kovač Peić, Hrvoje Holik & Božena Coha. (2017) Neuroendocrine tumor of cecum in patient treated with imatinib mesylate for blastic phase of chronic myeloid leukemia. Acta Clinica Belgica 72:6, pages 461-464.
Read now
Read now
Andrés Gomez-de-León, David Gómez-Almaguer, Guillermo J. Ruiz-Delgado & Guillermo J. Ruiz-Arguelles. (2017) Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective. Expert Review of Hematology 10:9, pages 809-819.
Read now
Read now
Tariq I. Mughal, Omar Abdel-Wahab, Raajit Rampal, Ruben Mesa, Steffen Koschmieder, Ross Levine, Rüdiger Hehlmann, Giuseppe Saglio, Tiziano Barbui & Richard A. Van Etten. (2016) Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Leukemia & Lymphoma 57:7, pages 1517-1526.
Read now
Read now
Enaam Alsobhi, Mohammed Burhan Abrar, Mohammed Abdelaal, Ahmed Alsaeed, Ahmed Absi, Zayed Alzahrani, Ihab El-Hemaidi, Mohammed Ali Alshehri, Ashraf Warsi, Safaa Bayashoot, Heba Hashem, Anas Merdad, Suhaib Radi, Hanadi Shiekhi & Abdulfattah Al-Amri. (2015) Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study. Leukemia & Lymphoma 56:4, pages 882-886.
Read now
Read now
Articles from other publishers (24)
Dana Merin, Akshaya Krishna, Sreelekshmi Jayakumar, A Mahima, K N Anila & Neeraj Sidharthan. (2022) Assessment of Imatinib as a Primary Treatment of Chronic Myeloid Leukemia in Chronic Phase: a Cohort Study. Journal of Oncology Pharmacy Practice 29:3, pages 547-556.
Crossref
Crossref
Avinash Kumar Singh, Arya Vidyadhari, Dinesh Bhurani, Narendra Agrawal, Rayaz Ahmed & Manju Sharma. (2023) Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients. Journal of Oncology Pharmacy Practice, pages 107815522311601.
Crossref
Crossref
Aakash Kumar S, Snehal S Patel, Shreya Patel & Palak Parikh. (2022) Future treatment of Diabetes – Tyrosine Kinase inhibitors. Journal of Diabetes & Metabolic Disorders 22:1, pages 61-71.
Crossref
Crossref
Olfa Kassar, Aicha Ben Kahla, Asma Koubaa, Faten Kallel, Imen Ben Amor & Moez Elloumi. (2022) Non-Hodgkin's lymphoma developed during imatinib mesylate treatment of chronic myeloid leukemia. Journal of Oncology Pharmacy Practice, pages 107815522211377.
Crossref
Crossref
Tatsuyuki Kono, Ayaka Abe, Kana Uchida, Yoshihiro Takahashi & Kenji Kawano. (2022) Imatinib-induced hyperpigmentation of the hard palate in a Japanese patient with chronic myeloid leukemia: A case report. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 34:6, pages 842-844.
Crossref
Crossref
Fan Yang, Nathachit Limjunyawong, Qi Peng, John T. Schroeder, Sarbjit Saini, Donald MacGlashanJrJr, Xinzhong Dong & Li Gao. (2022) Biological screening of a unique drug library targeting MRGPRX2. Frontiers in Immunology 13.
Crossref
Crossref
Faten Kallel, Olfa Kassar, Imen Maaloul, Maha Charfi, Kamilia Ksouda & Moez Elloumi. (2020) Hypersensitivity pneumonitis related to imatinib mesylate therapy in a patient with chronic myeloid leukemia. Journal of Oncology Pharmacy Practice 27:7, pages 1762-1765.
Crossref
Crossref
Javad Sharifi-Rad, Cristina Quispe, Zhazira Mukazhanova, Ewa Knut, Aknur Turgumbayeva, Aliya Kipchakbayeva, Gulnaz Seitimova, Mohamad Fawzi Mahomoodally, Devina Lobine, Aaron Koay, Jinfan Wang, Helen Sheridan, Gerardo Leyva-Gómez, María L. Del Prado-Audelo, Hernán Cortes, Antonio Rescigno, Paolo Zucca, Oksana Sytar, Muhammad Imran, Célia F. Rodrigues, Natália Cruz-Martins, Halina Ekiert, Manoj Kumar, Ahmad Faizal Abdull Razis, Usman Sunusi, Ramla Muhammad Kamal & Agnieszka Szopa. (2021) Resveratrol-Based Nanoformulations as an Emerging Therapeutic Strategy for Cancer. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
Michele Basile, Filippo Rumi & Americo Cicchetti. (2021) Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia. Global & Regional Health Technology Assessment 8, pages 87-95.
Crossref
Crossref
Cyril Sobolewski & Noémie Legrand. (2021) Celecoxib Analogues for Cancer Treatment: An Update on OSU-03012 and 2,5-Dimethyl-Celecoxib. Biomolecules 11:7, pages 1049.
Crossref
Crossref
Abhijit Phukan, Prakas Kumar Mandal & Tuphan K. Dolai. (2020) Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India. Annals of Hematology 100:1, pages 85-96.
Crossref
Crossref
Sinara Mônica Vitalino de Almeida, José Cleberson Santos Soares, Keriolaine Lima dos Santos, Josival Emanuel Ferreira Alves, Amélia Galdino Ribeiro, Íris Trindade Tenório Jacob, Cindy Juliane da Silva Ferreira, Jéssica Celerino dos Santos, Jamerson Ferreira de Oliveira, Luiz Bezerra de Carvalho Junior & Maria do Carmo Alves de Lima. (2020) COVID-19 therapy: What weapons do we bring into battle?. Bioorganic & Medicinal Chemistry 28:23, pages 115757.
Crossref
Crossref
Fabrizio Angaroni, Alex Graudenzi, Marco Rossignolo, Davide Maspero, Tommaso Calarco, Rocco Piazza, Simone Montangero & Marco Antoniotti. (2020) An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments. Frontiers in Bioengineering and Biotechnology 8.
Crossref
Crossref
Abduelmula R. Abduelkarem, Hanan S. Anbar, Seyed-Omar Zaraei, Aya A. Alfar, Omayma S. Al-Zoubi, Eveen G. Abdelkarem & Mohammed I. El-Gamal. (2020) Diarylamides in anticancer drug discovery: A review of pre-clinical and clinical investigations. European Journal of Medicinal Chemistry 188, pages 112029.
Crossref
Crossref
Thikrayat Al-Attar & Sundararajan V. Madihally. (2020) Modeling the impact of fluid flow on resveratrol release from electrospun fibers. Computers in Biology and Medicine 117, pages 103622.
Crossref
Crossref
D. Samuel Metibemu, O. Adeboye Akinloye, A. Jamiu Akamo, D. Ajiboye Ojo, O. Tolulope Okeowo & I. Olaposi Omotuyi. (2019) Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. Egyptian Journal of Medical Human Genetics 20:1.
Crossref
Crossref
Ji Hoon Jung, Ji Eon Park, Deok Yong Sim, Eunji Im, Woon Yi Park, Duckgue Lee, Bum-Sang Shim & Sung-Hoon Kim. (2019) Farnesiferol C Induces Apoptosis in Chronic Myelogenous Leukemia Cells as an Imatinib Sensitizer via Caspase Activation and HDAC (Histone Deacetylase) Inactivation. International Journal of Molecular Sciences 20:22, pages 5535.
Crossref
Crossref
Thikrayat Al-Attar & Sundararajan V. Madihally. (2019) Targeted cancer treatment using a combination of siRNA-liposomes and resveratrol-electrospun fibers in co-cultures. International Journal of Pharmaceutics 569, pages 118599.
Crossref
Crossref
Nader Ahmadi, Seyed-Mohammadreza Samaee, Robert A. Yokel & Aliasghar Tehrani. (2019) Imatinib mesylate effects on zebrafish reproductive success: Gonadal development, gamete quality, fertility, embryo-larvae viability and development, and related genes. Toxicology and Applied Pharmacology 379, pages 114645.
Crossref
Crossref
Hsinyi Tsang, KanakaDurga Addepalli & Sean R. Davis. (2017) Resources for Interpreting Variants in Precision Genomic Oncology Applications. Frontiers in Oncology 7.
Crossref
Crossref
Mark R. Wick & Alejandro A. Gru. (2016) Metastatic melanoma: Pathologic characterization, current treatment, and complications of therapy. Seminars in Diagnostic Pathology 33:4, pages 204-218.
Crossref
Crossref
Emina Vorkapic, Elma Dugic, Svante Vikingsson, Joy Roy, Mikko I. Mäyränpää, Per Eriksson & Dick Wågsäter. (2016) Imatinib treatment attenuates growth and inflammation of angiotensin II induced abdominal aortic aneurysm. Atherosclerosis 249, pages 101-109.
Crossref
Crossref
Fatou Samba Diago Ndiaye, Seynabou Fall, Abibatou Sall, Awa Oumar Touré, Atoumane Faye, Nafissatou Diagne & Abdoulaye Pouye. (2015) Adverse effects of Imatinib Mesylat: 5-year follow-up of 55 patients with chronic myeloid leukemia in Dakar (S�n�gal). Open Journal of Hematology 6, pages 1.
Crossref
Crossref
Ozgur Tanriverdi, Mustafa Unubol, Fisun Taskin, Nezih Meydan, Gokhan Sargin, Engin Guney & Sabri Barutca. (2011) Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: A literature review. Journal of Oncology Pharmacy Practice 18:2, pages 303-310.
Crossref
Crossref